Lexaria’s DehydraTECH™ Triples Bioavailability of CBD in Human Trial
August 3rd, 2018
News, Top News, Top Story
The cannabidiol (CBD) market is projected to reach $2.1 billion by 2020, according to the Hemp Business Journal, which marks significant growth over last year’s roughly $200 million in revenue. Consumers and physicians are starting to realize the significant potential benefits of the cannabinoid in treating a wide range of disorders that can be tied back to the human endocannabinoid system and its far-reaching effects.
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) has spent the past several years focused on improving the bioavailability of cannabinoids, including CBD. Its DehydraTECH™ drug delivery platform has demonstrated significant improvements in bioavailability over conventional delivery methods — and its latest human clinical study confirmed these findings. Lexaria is now one of a very few select biotech companies to have completed a successful human clinical trial with cannabinoids.
CBD Bioavailability Issues
There are many different cannabidiol (CBD) delivery methods available for consumers, patients, and physicians, including capsules, tinctures, vape oils, and even edibles, and each delivery method impacts the body in a different way. Most importantly, some delivery methods are associated with greater bioavailability — or the percentage of the compound that’s absorbed into the bloodstream after any other processing in the body.
Oral CBD supplements, such as capsules, edibles, and oils, must pass through the digestive system and circulate through the liver. These processes metabolize CBD and reduce the amount that ultimately reaches the bloodstream, thereby reducing the bioavailability. While there aren’t any studies about CBD bioavailability, there are some studies that have shown tetrahydrocannabinol (THC) bioavailability of between four and 20 percent for oral delivery.
Another common way to consume CBD is through inhalation using CBD vape oils. When a consumer vapes oil, CBD bypasses first-pass metabolism and enters the bloodstream through the lungs. THC studies have shown that this can enhance bioavailability to as much as 56 percent, although there is significant variance due to factors like how long the vapor is held in the lungs and the volume of inhalation for a given person.
Lexaria’s DehydraTECH™ drug delivery platform aims to improve bioavailability, as well as make the dosing more predictable across individuals.
By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver (first pass metabolism). Early animal studies showed that this approach could significant improve the bioavailability of cannabinoids.
On August 1, the company released the results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™ — a proprietary DehydraTECH™ powered CBD hemp oil capsule. The study looked at the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancements in 12 healthy male volunteers.
The study found that CBD absorption was more than three-times higher than the control at the 30 minute mark and continued to significantly surpass control blood level concentrations through the 360 minute measurements. Interestingly, the CBD absorption was even better than GW Pharmaceuticals’ (NASDAQ: GWPH) Mount Sinai study, which used much higher doses of 400mg and 800mg to achieve lower overall blood concentrations.
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) DehydraTECH™ has consistently demonstrated superior bioavailability versus other products on the market. In addition to CBD, the company has been actively research the drug delivery platform’s potential in improving the bioavailability of other cannabinoids and other drugs. It has over 40 patents pending and 8 patents granted around the world protecting these innovations, yielding significant licensing opportunities down the road.
For more information, visit the company’s website at www.lexariabiosciences.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.